심장 안전 서비스 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the cardiac safety service market size is projected to expand from USD 0.94 billion in 2025 and USD 1.04 billion in 2026 to USD 1.75 billion by 2031, registering a CAGR of 11.09% between 2026 to 2031.

This report is Segmented by Service Type (Thorough QT/QTc Study Services, ECG & Holter Monitoring Analysis, Blood Pressure & Telemetry Analysis, and More), Service Delivery Model (In-House, and More), Clinical Trial Phase (Phase I, and More), End User (Pharmaceutical Companies, and More), and Geography (North America, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Cardiac Safety Service Market Trends and Insights

Expanding Adoption of Decentralized & Hybrid Trials

Decentralized cardiac safety workflows grew from 12% of cardiovascular studies in 2023 to 28% in 2025. Remote Holter patches transmit encrypted ECG streams to cloud servers that flag QTc drift within hours, satisfying the FDA's 2024 digital-health guidance. Hybrid approaches blend at-home telemetry with site-based echocardiography, lowering patient travel costs by 40% while preserving imaging rigor. Vendors such as Clario fielded 15,000 wearable devices across oncology protocols in 2025, using machine-learning algorithms to escalate arrhythmia alerts automatically. Centralized over-reads mitigate regional cardiologist shortages, enabling multicountry enrollment without sacrificing data quality.

Rising Incidence of Cardiovascular Adverse Events in Oncology Trials

Cardiovascular toxicities ranked second among serious adverse events in cancer trials during 2024. Tyrosine-kinase inhibitors and immune checkpoint agents prolong QT or provoke myocarditis, prompting FDA safety communications that now require intensified ECG surveillance in early-phase oncology protocols. Updated 2025 European Society of Cardiology guidelines recommend pairing ECG monitoring with biomarkers and imaging, raising per-patient costs by 35% but cutting late-stage attrition. Real-time telemetry detects silent arrhythmias during dose escalation cohorts, a differentiator cited by Charles River in recent oncology contract wins. The resulting demand surge broadens the cardiac safety service market beyond traditional small-molecule programs.

Limited Global Harmonization of QT/QTc Assessment Standards

Regional regulators apply different QTc correction formulas and risk thresholds, forcing sponsors to run duplicate analyses that can delay approvals by up to three months. China still favors Bazett correction while the FDA and EMA prefer Fridericia, and Japan demands ethnic-sensitivity studies in Japanese volunteers, adding USD 1.5-2 million per program. Divergent cut-off values-480 ms in some jurisdictions versus 500 ms elsewhere-create uncertainty for data-safety boards and complicate dose-escalation decisions. The ICH working group began drafting unified correction guidance in 2025, yet final text is unlikely before 2028. Until then the cardiac safety service market will continue to bear redundant statistical costs that erode trial budgets and elongate timelines.

Other drivers and restraints analyzed in the detailed report include:

1. Stricter ICH E14/S7B 2022 Addendum Implementation
2. Growth of Real-Time Cloud-ECG Analytics Platforms
3. High Cost & Complexity of Comprehensive Cardiac Safety Studies

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The real-time data analytics and reporting segment grew to 14.24% CAGR, the fastest within the cardiac safety service market, as sponsors now expect same-day arrhythmia alerts for dose-escalation decisions. ECG and Holter monitoring maintained a 37.42% revenue lead in 2025 because 12-lead Holters remain mandatory in pivotal protocols. Thorough-QT study services contributed about 22% but lag due to the E14/S7B addendum that lets exposure-response modeling replace dedicated crossover trials. Blood-pressure telemetry posted 10.8% growth as oncology programs pair hemodynamic data with ECG to profile VEGF inhibitor risk. Cardiovascular imaging accounted for roughly 15% and climbs steadily because cardio-oncology guidelines call for serial left-ventricular ejection fraction checks.

Sponsors view real-time analytics as central to adaptive trial designs that modify dosing on the fly, something retrospective batches cannot support. Clario reports its machine-learning triage trims cardiologist review time 35%, underscoring why the cardiac safety service market favors algorithm-enabled workflows. Crossover thorough-QT remains vital for compounds with unknown ion-channel profiles, yet its USD 1.2 million price tag pushes many biotechnology firms toward integrated Phase I monitoring instead. Hybrid devices now combine blood-pressure cuffs and ECG patches in one transmitter, cutting procurement spend 20% and easing subject compliance. Imaging growth is tempered by the site-visit requirement, but the FDA's cardio-oncology draft in 2024 guarantees baseline and on-treatment scans for high-risk drugs, sustaining volume within the cardiac safety service market

Outsourced providers controlled 72.53% revenue in 2025, yet in-house units are set to expand 12.52% over 2026-2031 as large pharmaceutical companies install subscription software behind their firewalls. Internalization protects raw ECG files, eases GDPR and PIPL compliance, and lowers unit costs across long portfolios, fueling a shift within the cardiac safety service market. Eli Lilly's internal core lab now processes data from 20 concurrent studies and saves USD 8 million annually, a model other multinationals will likely mirror.

Outsourcing remains dominant for small biotechnology firms that lack cardiology staff or capital to buy hardware. Multicountry Phase III trials depend on vendors with 24-hour multilingual support, a scale only the largest contract research organizations provide. Smaller CROs form alliances to stay relevant; PSI and Richmond Pharmacology teamed up in 2025 to share cardiologist networks and broaden reach. Regulators scrutinize sponsor-run labs closely: twelve FDA inspection findings in 2024 cited inadequate QC, reminding smaller companies why outsourced oversight still matters. Hybrid models blending sponsor data capture with independent over-reads may become the norm as the cardiac safety service market balances cost, speed, and compliance.

Complete Report Scope:

• By Service Type
  • Thorough QT/QTc Study Services
  • ECG & Holter Monitoring Analysis
  • Blood Pressure & Telemetry Analysis
  • Cardiovascular Imaging (Echocardiography, MUGA)
  • Real-Time Data Analytics & Reporting
• By Service Delivery Model
  • In-house (Sponsor-run)
  • Outsourced (CRO & Specialist Vendors)
• By Clinical Trial Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV / Post-marketing
• By End User
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Medical Device Manufacturers
  • Contract Research Organisations (CROs)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 39.14% of 2025 revenue because FDA enforcement of the E14/S7B addendum anchors first-in-human activity, yet its growth moderates to 10.45% as sponsors diversify early-phase work into cost-efficient regions. Europe after adoption of Regulation (EU) 536/2014 streamlined cross-border ECG exchange, though GDPR amendments extend start-up paperwork and temper its expansion.EU. Asia-Pacific is the fastest mover, projected at 13.63% CAGR, propelled by China's 2024 cardiac safety guidance that aligns with Fridericia correction and India's investment in ISO 13485 core labs.

Middle East and Africa will grow as Gulf Cooperation Council nations invest USD 500 million in compliant research centers, aiming to diversify beyond oil. South America held 8% and expands 11.7% after Brazil's regulator aligned QT rules with ICH standards, while Argentina's economic stabilization revives Buenos Aires as a trial hub. Data-sovereignty laws in Europe, China, and India fragment telemetry workflows, forcing redundant infrastructure that raises per-patient costs and redistributes spend within the cardiac safety service market.

Asia-Pacific's large treatment-naive population lets Phase II and III trials finish six to nine months faster than in Western regions, a benefit WuXi Clinical highlights to multinational sponsors. North America remains the regulatory bellwether; FDA draft guidance on AI biomarkers issued in 2024 has shaped global adoption curves, keeping many pilot studies domestic despite cost concerns. European share is influenced by Brexit fragmentation that forces dual submissions to EMA and the UK regulator, adding administrative load and tilting some Phase I volumes toward the Netherlands and Belgium. Sub-Saharan Africa's potential is constrained by bandwidth and cardiologist shortages, yet tele-reading partnerships with European labs gradually open new recruitment corridors.

1. Banook Group
2. Celerion
3. Certara
4. Charles River
5. Clario (ERT & Bioclinica)
6. Clinilabs Drug Development Corp
7. Frontage Laboratories
8. ICON
9. In Vitro Technologies (CardioQuick)
10. IQVIA
11. Koninklijke Philips
12. LabCorp
13. MedPace
14. Ncardia
15. Parexel International
16. PSI CRO
17. Richmond Pharmacology
18. SGS Life Sciences
19. Thermo Fisher Scientific
20. Worldwide Clinical Trials
21. WuXi Clinical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expanding Adoption of Decentralized & Hybrid Trials
  • 4.2.2 Rising Incidence of Cardiovascular Adverse Events in Oncology Trials
  • 4.2.3 Stricter ICH E14/S7B 2022 Addendum Implementation
  • 4.2.4 Growth of Real-Time Cloud-ECG Analytics Platforms
  • 4.2.5 AI-Enabled Arrhythmia Prediction Reducing Late-Stage Failures
  • 4.2.6 Integration Of In-Silico Proarrhythmia Models into Safety Workflows
• 4.3 Market Restraints
  • 4.3.1 Limited Global Harmonization Of QT/QTc Assessment Standards
  • 4.3.2 High Capital Cost For 12-Lead Telemetry Infrastructure
  • 4.3.3 Data-Privacy Restrictions on Cross-Border ECG Transfer
  • 4.3.4 Scarcity of Certified Cardiac Safety Cardiologists in Emerging Markets
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Threat of Substitutes
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Bargaining Power of Buyers
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Service Type
  • 5.1.1 Thorough QT/QTc Study Services
  • 5.1.2 ECG & Holter Monitoring Analysis
  • 5.1.3 Blood Pressure & Telemetry Analysis
  • 5.1.4 Cardiovascular Imaging (Echocardiography, MUGA)
  • 5.1.5 Real-Time Data Analytics & Reporting
• 5.2 By Service Delivery Model
  • 5.2.1 In-house (Sponsor-run)
  • 5.2.2 Outsourced (CRO & Specialist Vendors)
• 5.3 By Clinical Trial Phase
  • 5.3.1 Phase I
  • 5.3.2 Phase II
  • 5.3.3 Phase III
  • 5.3.4 Phase IV / Post-marketing
• 5.4 By End User
  • 5.4.1 Pharmaceutical Companies
  • 5.4.2 Biotechnology Firms
  • 5.4.3 Medical Device Manufacturers
  • 5.4.4 Contract Research Organisations (CROs)
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 France
    • 5.5.2.3 United Kingdom
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.3.1 Banook Group
  • 6.3.2 Celerion
  • 6.3.3 Certara
  • 6.3.4 Charles River Laboratories
  • 6.3.5 Clario (ERT & Bioclinica)
  • 6.3.6 Clinilabs Drug Development Corp
  • 6.3.7 Frontage Laboratories
  • 6.3.8 ICON plc
  • 6.3.9 In Vitro Technologies (CardioQuick)
  • 6.3.10 IQVIA
  • 6.3.11 Koninklijke Philips N.V
  • 6.3.12 Labcorp Drug Development (Covance)
  • 6.3.13 Medpace
  • 6.3.14 Ncardia
  • 6.3.15 Parexel
  • 6.3.16 PSI CRO
  • 6.3.17 Richmond Pharmacology
  • 6.3.18 SGS Life Sciences
  • 6.3.19 Thermo Fisher Scientific
  • 6.3.20 Worldwide Clinical Trials
  • 6.3.21 WuXi Clinical

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment